Key Technologies
Age-Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR)
AMD and DR are some of the leading causes of blindness in patients aged 40 years and older.
Age-Related Macular Degeneration
Diabetic Retinopathy
Wet AMD and proliferative DR are characterized by abnormal retinal neovascularization. The current standard of care is intravitreal injection of anti-vascular epithelial growth factor (anti-VEGF). While effective, this is an invasive treatment method that causes patient discomfort and can lead to side effects including infection, bleeding, and retinal detachment. NexThera is developing a non-invasive, peptide-based eye drop therapy for wet AMD (NT-101) and DR (NT-102) as a safer and more convenient solution for patients.
Intravitreal injection
Eye drop therapy
NT-101
•NexThera’s eye drop therapy delivers PEDF, a peptide that inhibits angiogenesis, into the retina.
•The efficacy of NT-101 was demonstrated to be equivalent or greater than that of EYLEA (an approved treatment for wet AMD that is administered via intravitreal injection) in rodent models.
Preventive effect
Control
Eylea
NT-101
Therapeutic effect
Control
NT-101
Technology Applicability
Biobetter Development Technology
Functional Peptide Nanostructures
Antibody Fragment Nanostructures
Protein Nanostructures
Drug-Loaded Nanostructures
Protein translation inhibition as anti-cancer strategy
Strong mRNA /
weak mRNA hypothesis
weak mRNA hypothesis
• mTOR inhibitors (rapamycin and derivatives)
• 4E-BP regulators
• Inhibitors of 4E and 4G interaction
• Inhibitors of mRNA 5’-Cap interaction
Protein translation initiation
HRI is the erythroid specific regulator of eIF2𝝰
NT-301 (HR-19011), cell cycle arrest inducing agent
Schematic diagram of
NT-301 mechanism
NT-301 mechanism
NT-321 (HR-18020), apoptosis inducing agent
Schematic diagram of
NT-301 mechanism
NT-301 mechanism
NT-341 (HR-20017), autophagy inducing agent
• HR-20017-induced phosphorylation of eIF2𝜶 not only showed HRI- dependent activity, but also induced phosphorylation of PERK.
• HR-20017 induced ROS and caspase-independent cell death.
• HR-20017 inhibited the mTOR pathway and induced autophagy cell death.
Patent number
10-2016-0053154
Registration number
10-1906494
Patent filing date
2017. 06. 08
Registration date
2018. 10. 02
